New drug may tame immunotherapy skin rash and keep cancer treatment on track
NCT ID NCT06715982
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests a JAK inhibitor drug (upadacitinib) for cancer patients who develop a severe skin rash from immunotherapy. The goal is to quickly relieve the rash without using steroids, which can weaken the cancer treatment. About 35 adults with solid tumors and grade 3-4 rash will take the drug, and researchers will track rash improvement and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITORS (ICI)-RELATED DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quzhou people's hospital
RECRUITINGQuzhou, Zhejiang, 324000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.